#Bayer's mineralocorticoid receptor antagonist (MRA) #Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic #kidneydisease (CKD).

buff.ly/JIVSDre

FDA expands Bayer’s Kerendia label to include certain heart failure patients The drug is part of an expanding cardio-renal-metabolic care portfolio, is approved for CKD associated with type 2 diabetes.

The US FDA has approved Bayer’s Kerendia (finerenone) for adults with heart failure and left ventricular ejection fraction (LVEF) of 40% or higher.

#news #KERENDIA #HeartFailure #HFpEF #HFmrEF #Cardiology #HeartHealth #FDAApproval #PharmaNews #DrugApproval

FDA expands Bayer’s Kerendia label to include certain heart failure patients The drug is part of an expanding cardio-renal-metabolic care portfolio, is approved for CKD associated with type 2 diabetes.

The US FDA has approved Bayer’s Kerendia (finerenone) for adults with heart failure and left ventricular ejection fraction (LVEF) of 40% or higher.

#news #KERENDIA #HeartFailure #HFpEF #HFmrEF #Cardiology #HeartHealth #FDAApproval #PharmaNews #DrugApproval

Bayer gets sought-after heart failure use for Kerendia Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects.

#Bayer's mineralocorticoid receptor antagonist (MRA) #Kerendia has won FDA approval for a new #heartfailure indication thought to be pivotal for the product's sales prospects.

pharmaphorum.com/news/bayer-g...

Bayer will Zulassung von Kerendia gegen Herzinsuffizienz - Studiendetails Bayer strebt für sein Nierenmedikament Kerendia auch eine Zulassung zur Behandlung von Herzinsuffizienz an. Grundlage sind detaillierte Ergebnisse der Finearts-HF-Studie zu Finerenon , die Bayer am...

Bayer strebt für sein #Nierenmedikament #Kerendia auch eine Zulassung zur Behandlung von Behandlung von Herzinsuffizienz an.

de.marketscreener.com/kurs/aktie/B...